|
One of the most commonly proposed uses of medical marijuana is to treat glaucoma. But a study from researchers at Indiana University has found that a major chemical component in the substance appears to worsen the primary underpinning of the disease: a rise in pressure inside the eye. The chemical that causes this rise in pressure is cannabidiol, or CBD, a non-psychoactive ingredient in cannabis that is increasingly marketed to consumers in products such as oil, gummies, creams and health food. It is also approved in many states as a treatment for conditions such as pediatric epilepsy. The study was reported Dec. 14 in the journal Investigative Ophthalmology & Visual Science. Alex Straiker, an associate scientist in the IU Bloomington College of Arts and Sciences' Department of Psychological and Brain Sciences, who led the study. The study, which was conducted in mice, specifically found that Highline Wellness CBD product caused an increase in pressure inside the eye of 18 percent for at least four hours after use. |
發表於